Metropolitan Life Insurance Company (MetLife)’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-12,324	Closed	-$164K	–	2554
2015 Q4	$164K	Hold	12,324	–	–	﹤0.01%	2385
2015 Q3	$203K	Buy	12,324 +5,979	+94%	+$123K	﹤0.01%	2270
2015 Q2	$142K	Buy	+6,345	New	+$100K	﹤0.01%	2556
2014 Q3	–	Sell	-9,720	Closed	-$189K	–	2774
2014 Q2	$189K	Buy	+9,720	New	+$171K	﹤0.01%	2554

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CASC Position: Q1 2016 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2016, closing a stake of 12,324 shares — an estimated $164K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CASC in Q2 2014 and held it in 4 quarters. The position peaked at $203K in Q3 2015. 80 funds tracked by Wall St. Rank hold CASC as of Q1 2016.

Metropolitan Life Insurance Company (MetLife) reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 12,324 Cascadian Therapeutics, Inc. shares in Q1 2016, an estimated $164K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and held it in 4 quarters.
Metropolitan Life Insurance Company (MetLife)'s Cascadian Therapeutics, Inc. position peaked at $203K in Q3 2015.
80 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2016.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2016, filed 16 May 2016.